upper
respiratori
tract
infect
urti
present
clinic
common
cold
common
human
ill
multipl
respiratori
virus
known
caus
episod
urti
howev
rhinoviru
consist
identifi
common
caus
common
cold
major
infect
mild
selflimit
urti
exacerb
exist
medic
condit
caus
sever
ill
may
result
hospit
death
observ
studi
consist
demonstr
associ
low
vitamin
level
greater
frequenc
sever
urti
children
adult
result
sever
trial
vitamin
supplement
report
reduc
risk
infect
three
studi
report
statist
signific
find
lack
consensu
among
studi
may
reflect
substanti
heterogen
across
trial
result
variat
particip
popul
degre
vitamin
defici
dose
durat
vitamin
supplement
definit
urti
addit
sever
trial
limit
retrospect
data
collect
posthoc
analys
trial
nonrespiratori
outcom
consequ
remain
need
rigorouslydesign
larg
clinic
trial
investig
effect
vitamin
urti
healthi
popul
japan
daili
gargl
water
recommend
prevent
measur
urti
result
japanes
trial
report
reduct
incid
urti
amongst
particip
random
gargl
water
three
time
daili
compar
control
group
current
studi
design
assess
effect
vitamin
supplement
versu
placebo
gargl
versu
nogargl
prevent
urti
univers
student
conduct
factori
rct
vitamin
versu
placebo
gargl
versu
nogargl
student
mcmaster
univers
hamilton
ontario
particip
enrol
first
two
week
septemb
follow
end
octob
respect
individu
elig
studi
enrol
mcmaster
univers
year
live
least
one
student
housem
particip
contraind
medic
condit
hypercalcemia
parathyroid
disord
chronic
kidney
diseas
use
anticonvuls
malabsorpt
syndrom
sarcoidosi
current
plan
becom
pregnant
take
intern
unit
iu
day
vitamin
unabl
swallow
capsul
exclud
particip
provid
written
consent
studi
protocol
approv
hamilton
health
sciencesfaculti
health
scienc
research
ethic
board
regist
clinicaltrialsgov
particip
complet
baselin
questionnair
collect
demograph
health
lifestyl
inform
submit
selfcollect
midturbin
flock
nasal
swab
copan
italia
brescia
itali
particip
random
one
four
alloc
arm
vitamin
gargl
vitamin
gargl
placebo
gargl
placebo
gargl
studi
sampl
stratifi
base
hous
resid
versu
offcampu
block
random
occur
within
stratum
use
alloc
ratio
studi
pharmacist
knew
random
scheme
alloc
conceal
use
opaqu
seal
serial
number
envelop
prevent
violat
alloc
conceal
envelop
could
access
two
studi
personnel
involv
prepar
envelop
access
personnel
present
size
random
block
known
studi
doubleblind
respect
vitamin
intervent
due
natur
gargl
intervent
particip
random
gargl
blind
particip
studi
personnel
remain
blind
particip
random
receiv
contain
eight
capsul
either
iu
activ
vitamin
ident
placebo
particip
instruct
take
one
pill
weekli
receiv
weekli
email
remind
individu
random
gargl
intervent
ask
gargl
approxim
ml
tap
water
second
twice
daili
particip
receiv
gener
lifestyl
health
advic
benefit
appropri
sleep
nutrit
hand
hygien
exercis
time
random
intervent
alloc
occur
via
serial
number
pill
contain
opaqu
envelop
contain
gargl
alloc
given
directli
particip
vitamin
purchas
europharm
intern
canada
inc
placebo
contain
calcium
carbon
pill
made
aesthet
ident
use
gelatin
capsul
particip
ask
complet
weekli
onlin
survey
screen
urti
symptom
submit
one
selfcollect
nasal
swab
weekli
particip
urti
ask
complet
symptom
survey
seven
consecut
day
follow
symptom
onset
followup
survey
day
symptom
onset
also
ask
collect
seven
consecut
daili
nasal
swab
start
symptom
onset
swab
store
room
temperatur
transport
medium
copan
italia
brescia
itali
alcoholbas
medium
inactiv
respiratori
virus
contact
swab
submit
symptomat
particip
test
respiratori
virus
swab
store
separ
studi
includ
investig
asymptomat
ill
primari
outcom
incid
clinic
urti
defin
particip
percept
cold
conjunct
two
symptom
runnystuffi
nose
congest
cough
sneez
sore
throat
muscl
ach
fever
student
ask
immedi
electron
report
onset
cold
weekli
survey
ask
particip
consid
sick
adjud
two
clinician
appli
particip
report
symptom
uncertain
ill
report
deem
adjud
event
least
two
symptom
report
includ
one
nasal
congest
sneez
cough
sore
throat
wheez
addit
inform
provid
attribut
symptom
anoth
caus
selfreport
adjud
episod
clinic
urti
consid
event
onset
occur
least
seven
day
particip
random
date
secondari
outcom
includ
laboratori
confirm
ill
viral
load
symptom
durat
sever
laboratori
confirm
ill
determin
test
day
nasal
swab
use
inhous
enterovirusrhinoviru
polymeras
chain
reaction
pcr
neg
commerci
multiplex
pcr
abl
detect
respiratori
virus
viral
subtyp
xtag
rvp
fast
luminex
austin
tx
test
perform
identifi
bacteri
agent
viral
load
determin
rhinoviru
infect
use
quantit
pcr
symptom
sever
durat
measur
use
wisconsin
upper
respiratori
symptom
survey
symptom
sever
calcul
sum
seven
consecut
daili
sever
score
symptom
durat
defin
total
number
day
symptom
onset
particip
respond
feel
sick
today
enrol
particip
ask
frequenc
hand
wash
meal
averag
weekli
hour
exercis
averag
hour
sleep
per
night
current
vitamin
supplement
use
gargl
habit
well
asthma
smoke
statu
provid
inform
potenti
confound
mediat
moder
aim
recruit
uniqu
particip
ensur
greater
power
detect
reduct
proport
student
urti
overrecruit
adjust
attrit
studi
power
detect
main
effect
underpow
definit
investig
interact
poisson
regress
robust
standard
error
use
assess
primari
question
whether
vitamin
gargl
could
reduc
number
clinic
urti
experienc
group
analysi
chosen
place
logist
regress
sinc
odd
ratio
overestim
treatment
effect
incorrectli
interpret
risk
ratio
robust
standard
error
calcul
place
model
base
standard
error
typic
larg
multipl
imput
use
markov
chain
mont
carlo
method
conduct
address
miss
data
inform
collect
baselin
weekli
survey
use
predict
miss
valu
independ
depend
variabl
pool
imput
data
use
conduct
intentiontotreat
analysi
adjust
random
strata
hous
trial
year
vitamin
gargl
alloc
interact
vitamin
use
gargl
investig
use
crossproduct
term
complet
case
analysi
adjust
variabl
perform
sensit
analysi
ident
completecas
analysi
conduct
assess
secondari
outcom
laboratori
confirm
infect
symptom
sever
viral
load
log
viral
copiesml
compar
ttest
cox
regress
use
assess
time
symptom
resolut
adjust
variabl
list
analys
plan
priori
result
consid
statist
signific
p
statist
analys
conduct
use
ibm
spss
statist
softwar
version
ibm
spss
inc
chicago
il
usa
six
hundr
ninetyeight
prospect
particip
provid
written
consent
complet
baselin
survey
provid
nasal
swab
random
studi
four
hundr
seventi
one
complet
weekli
survey
complet
least
one
complet
none
figur
median
age
particip
year
interquartil
rang
first
second
year
undergradu
student
femal
baselin
characterist
similar
across
intervent
arm
tabl
clinic
urti
laboratori
confirm
data
avail
particip
respect
total
individu
experienc
symptomat
clinic
urti
episod
selfreport
episod
establish
adjud
laboratori
test
identifi
viral
pathogen
infect
rhinoviru
predomin
viral
pathogen
case
six
case
enteroviru
one
case
coronaviru
distinct
rhinoviru
enteroviru
establish
two
sampl
shown
tabl
fewer
particip
random
receiv
vitamin
report
clinic
urti
random
receiv
placebo
imput
analysi
p
complet
case
analysi
p
laboratori
confirm
event
significantli
lower
particip
receiv
vitamin
supplement
compar
receiv
placebo
p
tabl
eightyf
particip
assign
gargl
report
clinic
urti
compar
particip
assign
gargl
imput
analysi
rr
p
complet
case
analysi
rr
p
tabl
thirtythre
particip
assign
gargl
laboratori
confirm
urti
compar
particip
random
control
arm
howev
statist
signific
differ
tabl
rr
p
viral
load
establish
rhinoviru
infect
mean
viral
load
vitamin
group
lower
compar
placebo
group
viral
copiesml
versu
viral
copiesml
respect
mean
differ
p
tabl
mean
viral
load
assign
gargl
group
viral
copiesml
compar
viral
copiesml
control
group
mean
differ
p
tabl
mean
durat
clinic
laboratori
confirm
urti
nonsignificantli
lower
vitamin
group
compar
placebo
group
versu
day
versu
day
respect
time
symptom
resolut
significantli
differ
group
clinic
urti
hr
p
laboratori
confirm
urti
hr
p
tabl
gargl
reduc
mean
durat
symptom
improv
time
symptom
resolut
result
similar
clinic
urti
hr
p
laboratori
confirm
urti
p
tabl
mean
symptom
sever
appear
greater
vitamin
group
clinic
laboratori
confirm
urti
versu
versu
respect
tabl
howev
differ
statist
signific
symptom
sever
also
appear
greater
gargl
group
clinic
laboratori
confirm
urti
howev
statist
signific
versu
versu
respect
tabl
weekli
supplement
iu
vitamin
univers
student
septemb
octob
associ
nonsignific
potenti
clinic
import
risk
reduct
clinic
urti
importantli
vitamin
supplement
associ
statist
signific
risk
reduct
laboratori
confirm
urti
result
previou
trial
vitamin
supplement
prevent
urti
conflict
two
placebo
control
rct
pediatr
popul
one
trial
adult
primari
immun
suppress
demonstr
vitamin
significantli
reduc
risk
clinic
labconfirm
urti
improv
annual
infect
score
respect
howev
previou
trial
healthi
adult
popul
yield
statist
signific
result
effect
estim
studi
similar
report
pediatr
trial
urashima
et
al
report
children
age
receiv
daili
supplement
iu
vitamin
lower
risk
influenza
infect
camargo
et
al
report
risk
reduct
parentreport
urti
among
children
age
receiv
daili
supplement
iu
vitamin
consist
previou
studi
healthi
adult
primari
analysi
show
vitamin
significantli
reduc
risk
clinic
urti
howev
rel
risk
reduct
may
clinic
relev
ling
et
al
random
adult
iu
vitamin
placebo
daili
decemb
march
report
differ
selfreport
urti
laaksi
colleagu
random
men
iu
vitamin
placebo
daili
octob
march
detect
signific
differ
number
day
absent
duti
due
urti
howev
proport
men
experi
urti
significantli
greater
intervent
group
control
group
murdoch
et
al
follow
adult
random
monthli
dose
iu
vitamin
placebo
month
studi
record
urti
episod
vitamin
control
group
respect
howev
signific
differ
ree
et
al
perform
substudi
particip
trial
colorect
adenoma
chemoprevent
particip
random
receiv
iu
vitamin
calcium
carbon
placebo
daili
follow
averag
month
cover
two
winter
season
author
report
supplement
significantli
reduc
incid
urti
bergman
et
al
follow
adult
increas
suscept
respiratori
infect
immunodefici
clinic
one
year
daili
supplement
either
iu
vitamin
placebo
author
report
significantli
lower
infect
score
vitamin
group
notabl
priori
secondari
outcom
assess
laboratori
confirm
urti
demonstr
signific
rel
risk
reduct
associ
vitamin
supplement
result
consist
two
recent
metaanalys
charan
et
al
bergman
et
al
report
vitamin
supplement
significantli
decreas
odd
respiratori
infect
pool
p
p
respect
although
result
support
use
vitamin
supplement
metaanalysi
particularli
individu
patient
data
metaanalysi
includ
result
recent
trial
explor
heterogen
trial
conduct
research
demonstr
vitamin
play
role
innat
immun
respons
stimul
product
antimicrobi
peptid
defensin
cathelicidin
enhanc
microbicid
action
monocyt
macrophag
reason
hypothes
vitamin
supplement
might
reduc
amount
viru
infect
person
data
support
hypothesi
mean
log
viral
load
significantli
lower
vitamin
group
compar
placebo
group
studi
differ
sever
potenti
import
way
previou
studi
well
establish
vitamin
level
fluctuat
season
studi
canadian
demonstr
mark
drop
vitamin
level
fall
peak
level
summer
high
preval
low
wintertim
vitamin
level
captur
peak
rate
rhinoviru
infect
student
initi
intervent
earli
septemb
rather
late
autumn
winter
month
thu
serum
vitamin
level
opportun
declin
natur
would
autumn
rather
overcom
deplet
vitamin
level
studi
may
maintain
potenti
enhanc
vitamin
level
howev
absenc
blood
test
proven
addit
differ
includ
frequenc
quantiti
vitamin
supplement
studi
use
rel
high
dose
iu
vitamin
per
week
ingest
singl
dose
averag
approxim
iuday
although
optim
dose
regimen
remain
uncertain
acknowledg
adher
daili
supplement
often
suboptim
larger
less
frequent
dose
may
effect
altern
final
methodolog
differ
use
selfcollect
nasal
swab
laboratori
confirm
urti
definit
clinic
urti
may
excess
broad
insuffici
specif
may
led
incorrectli
classifi
event
possibl
definit
captur
episod
attribut
allergi
caus
creat
error
statist
model
push
result
toward
null
effect
ultim
studi
underpow
sinc
observ
event
rate
lower
predict
would
contribut
larger
varianc
estim
uncertainti
surround
result
studi
conduct
rel
short
period
time
captur
peak
rhinoviru
activ
unabl
captur
urti
caus
virus
consequ
uncertain
whether
vitamin
supplement
benefici
prevent
nonrhinoviru
urti
addit
limit
lack
serum
vitamin
test
without
unabl
investig
whether
individu
lower
baselin
vitamin
level
benefit
increment
compar
individu
suffici
baselin
vitamin
level
gargl
appear
reduc
risk
urti
studi
popul
contrast
previou
report
although
collect
period
captur
peak
rhinoviru
activ
gargl
may
effect
pathogen
predominantli
colon
oropharynx
addit
unabl
observ
whether
often
gargl
practic
particip
gargl
may
need
carri
frequent
twice
daili
benefici
find
support
grow
bodi
literatur
propos
vitamin
promis
intervent
prevent
urti
young
adult
studi
demonstr
vitamin
prevent
laboratori
confirm
acut
viral
respiratori
infect
vitamin
supplement
may
repres
effect
access
safe
intervent
prevent
urti
mani
question
might
guid
clinic
practic
remain
unansw
rigor
systemat
review
metaanalysi
current
studi
particularli
individu
patient
data
metaanalysi
would
facilit
evalu
potenti
variabl
interact
would
instrument
design
futur
trial
field
may
need
includ
larger
sampl
size
longer
period
followup
differ
dose
regimen
target
popul
may
benefit
disproportion
vitamin
supplement
confid
interv
iu
intern
unit
hr
hazard
ratio
pcr
polymeras
chain
reaction
rct
random
control
trial
rr
rel
risk
rrr
rel
risk
reduct
urti
upper
respiratori
tract
infect
author
declar
compet
interest
eg
full
access
studi
data
take
respons
integr
data
accuraci
data
analysi
eg
ms
ep
ml
particip
studi
design
develop
studi
conduct
supervis
conduct
eg
ms
eg
ag
kl
respons
acquisit
data
ag
kl
conduct
laboratori
test
analysi
interpret
data
conduct
eg
ep
ms
ml
bc
eg
draft
manuscript
author
critic
review
manuscript
intellectu
content
author
read
approv
final
manuscript
prepubl
histori
paper
access
http
